Abide Therapeutics

NEWS

Abide Therapeutics was acquired by Lundbeck in 2019.

Deals

Lundbeck Acquires Abide Therapeutics for $250M, Gains San Diego Discovery Site

With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.

May 6, 2019

2 min read

Alex Keown

IN THE PRESS

Business

Abide Therapeutics Appoints Kevin Finney as President and Chief Operating Officer

January 24, 2019

4 min read

Drug Development

Abide Therapeutics Announces Initiation of Phase 2 Clinical Trial of ABX-1431 in Tourette Syndrome

October 16, 2018

4 min read

Drug Development

Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting

April 10, 2018

3 min read

Business

Abide and Celgene Enter Worldwide License Agreement for ABX-1772

March 28, 2018

1 min read

Drug Development

Abide Therapeutics Reports Positive Topline Data From Phase Ib Study of ABX-1431 in Tourette Syndrome

November 28, 2017

6 min read

Drug Development

Abide Therapeutics Announces Dosing Of First Subject In Phase Ib Study Of ABX-1431 In Patients With Neuromyelitis Optica (NMO)

October 10, 2017

4 min read

Business

Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial And Strategy Officer

September 18, 2017

2 min read

Drug Development

Abide Therapeutics Announces Dosing Of First Subject In fMRI Imaging Study To Investigate Brain Activity Patterns Associated With ABX-1431

May 10, 2017

5 min read

Drug Development

Abide Therapeutics Announces Dosing Of First Patient In Phase Ib Study Of ABX-1431 In Tourette Syndrome And Collaboration With Tourette Association Of America

April 18, 2017

4 min read

Drug Development

Abide Therapeutics Announces First Patient Dosed In Phase 1b Study To Assess The Effect Of ABX-1431 In Patients With Functional Dyspepsia

December 14, 2016

3 min read

AWARDS

JOBS